Laboratory Analysis Report

Blood & Urine — Complete Metabolic Panel

Report ID: MAA-LAB-7B3F92
Generated: April 16, 2026
Analysis: AI-Powered Clinical Interpretation

Patient Profile

Sex:
Male
Age:
47 years
Height / Weight:
178 cm / 89 kg (BMI 28.1 — overweight)
Reported symptoms:
Persistent fatigue, mild jaundice noted by family, occasional right upper quadrant discomfort
Medications:
Atorvastatin 20 mg daily (3 years), occasional ibuprofen
Notable history:
Moderate alcohol intake (10–14 units/week), no known liver disease, last lipid screening 18 months ago

Summary Overview

Comprehensive metabolic and hematology panel with urinalysis. 15 parameters analyzed; 7 outside reference range, predominantly clustered in hepatic and lipid systems. Renal function preserved.

15
Parameters
7
Out of Range
8
Within Range

Body Systems Overview

Hematology1 of 4 abnormal
Liver function4 of 5 abnormal
Lipid panel2 of 3 abnormal
Kidney functionAll normal
Glucose / MetabolismAll normal
UrinalysisAll normal

Detailed Parameter Analysis

ALT (Alanine Aminotransferase)Out of Range
Result
285 U/L
Reference (lab)
7–55 U/L
Magnitude
5.2× ULN
ALT is the most liver-specific aminotransferase; values above 5× ULN indicate significant hepatocellular injury. The degree of elevation here is consistent with acute or subacute hepatic insult rather than chronic low-grade inflammation [Kwo PY, Am J Gastroenterol 2017]. Differential at this magnitude includes drug-induced liver injury (DILI), viral hepatitis, alcohol-related injury, and metabolic-dysfunction-associated steatotic liver disease (MASLD) with steatohepatitis [EASL Guidelines, J Hepatol 2017]. The patient's lipid-lowering therapy and reported alcohol intake are both potentially contributory.
AST (Aspartate Aminotransferase)Out of Range
Result
147 U/L
Reference (lab)
8–48 U/L
AST:ALT
0.52
AST elevation accompanies ALT, but the AST:ALT ratio of 0.52 (i.e., ALT > AST) argues against classic alcoholic hepatitis as the dominant driver, where the ratio typically exceeds 2 [Sorbi D, Am J Gastroenterol 1999]. The pattern is more characteristic of viral, drug-induced, or steatohepatitis injury. R-value calculation (ALT/ULN ÷ ALP/ULN) = 7.2 confirms a hepatocellular dominant injury pattern (R ≥ 5) [Kwo PY 2017].
GGT (Gamma-Glutamyl Transferase)Out of Range
Result
156 U/L
Reference (lab)
9–48 U/L
Magnitude
3.3× ULN
GGT is a sensitive but non-specific marker of hepatic stress; elevation in this context, with normal alkaline phosphatase, suggests parenchymal rather than cholestatic injury. GGT is also induced by alcohol and several medications, which is consistent with the clinical history. Combined with hepatocellular enzyme elevation, it strengthens the case for either alcohol-related injury or DILI.
Total BilirubinOut of Range
Result
2.4 mg/dL
Reference (lab)
0.2–1.2 mg/dL
Direct fraction
1.6 mg/dL (67%)
Total bilirubin is moderately elevated with predominantly conjugated (direct) fraction at 67%, consistent with hepatocellular or post-hepatic origin rather than hemolysis. This degree of conjugated hyperbilirubinemia in a patient with marked transaminase elevation supports clinically relevant liver injury and explains the family's observation of mild jaundice [EASL Cholestatic Liver Diseases Guidelines, J Hepatol 2017]. Imaging (abdominal ultrasound) is recommended to exclude biliary obstruction.
MCV (Mean Corpuscular Volume)Out of Range
Result
102 fL
Reference (lab)
80–100 fL
Hemoglobin
14.8 g/dL (normal)
Borderline macrocytosis without anemia. Common causes include alcohol use, vitamin B12 or folate deficiency, hypothyroidism, liver disease, and certain medications [Kaferle J, Am Fam Physician 2009]. In this clinical context — reported alcohol intake and hepatocellular injury — alcohol-related macrocytosis is the most parsimonious explanation, but a focused workup (B12, folate, TSH, reticulocyte count) is recommended to rule out concurrent contributors before attribution.
TriglyceridesOut of Range
Result
280 mg/dL
Reference (lab)
<150 mg/dL
Category
Borderline-high
Hypertriglyceridemia at this level is associated with increased atherosclerotic cardiovascular risk and, when persistent above 500 mg/dL, with pancreatitis risk [Berglund L et al., J Clin Endocrinol Metab 2012 — Endocrine Society Guidelines]. In a patient with overweight BMI, alcohol use, and suspected hepatic steatosis, this finding fits a metabolic-dysfunction-associated pattern. Lifestyle intervention (alcohol reduction, weight loss, dietary changes) is first-line.
HDL CholesterolOut of Range
Result
31 mg/dL
Reference (lab)
>40 mg/dL (men)
TG/HDL ratio
9.0 (high)
Low HDL combined with elevated triglycerides yields a TG/HDL ratio of 9, well above the <3.5 threshold associated with insulin sensitivity. This profile reinforces the metabolic-dysfunction picture. The combination is a known feature of MASLD and predicts higher cardiometabolic risk independently of LDL cholesterol.

Differential Diagnosis — Conditions to Discuss with Your Physician

  • Alcohol-related liver injuryHigh
    Reported intake of 10–14 units/week, hepatocellular pattern, GGT elevation, and macrocytosis collectively support this diagnosis. AST:ALT ratio < 1 is somewhat atypical for chronic alcohol-related injury, suggesting an acute superimposed component or coexisting etiology [EASL Guidelines, J Hepatol 2018].
  • Drug-induced liver injury (DILI) — statin-associatedModerate
    Atorvastatin can cause hepatocellular injury in 1–3% of users, typically dose-dependent and reversible upon discontinuation [Chalasani N, Gastroenterology 2014]. Three-year duration without prior elevation lowers but does not exclude probability. Concurrent NSAID use also possible contributor.
  • MASLD with steatohepatitisModerate
    Overweight BMI, dyslipidemia, and TG/HDL pattern are consistent with metabolic-dysfunction-associated steatotic liver disease [Rinella ME, Hepatology 2023]. Imaging (ultrasound or FibroScan) and FIB-4 calculation would help stratify fibrosis risk.
  • Viral hepatitis (B or C)Low–Moderate
    Cannot be excluded without serologic testing. Elevated transaminases of this magnitude warrant HBsAg, anti-HCV, and HBV core antibody screening per AASLD recommendations [AASLD Hepatitis Guidelines, current edition].
  • Biliary obstructionLow
    Conjugated hyperbilirubinemia raises this consideration, but normal alkaline phosphatase makes mechanical obstruction less likely. Right upper quadrant discomfort warrants abdominal ultrasound for definitive evaluation.

Analytical Summary & Recommendations

Clinical pattern

The dominant abnormality is a hepatocellular injury pattern (R-value 7.2) of moderate magnitude (ALT 5× ULN), with conjugated hyperbilirubinemia and clinical jaundice. Concurrent macrocytosis, elevated GGT, and atherogenic lipid profile in the context of reported alcohol intake and overweight status are most consistent with combined alcohol-related and metabolic liver injury, with statin-associated DILI as an additional consideration.

Recommended next investigations

  • Etiologic workup: HBsAg, anti-HCV, HBV core antibody, anti-HAV IgM (acute screen)
  • Imaging: Abdominal ultrasound — assess hepatic parenchyma, biliary tree, and exclude focal lesions
  • Fibrosis stratification: FIB-4 calculation (requires age, AST, ALT, platelets); consider FibroScan if FIB-4 is intermediate or high [Sterling RK, Hepatology 2006]
  • Macrocytosis workup: Vitamin B12, folate, TSH, reticulocyte count [Kaferle J 2009]
  • Statin assessment: Discuss with prescribing physician — temporary discontinuation may help establish causality if labs improve
  • Repeat liver panel in 4–6 weeks after intervention to assess trend

Lifestyle recommendations

  • Alcohol reduction (ideally cessation for 4–8 weeks) — diagnostic and therapeutic [EASL 2018]
  • Mediterranean-pattern diet, weight reduction targeting 7–10% body weight
  • Regular aerobic activity (≥150 min/week moderate intensity)
  • Avoid acetaminophen above 2 g/day; minimize NSAID use until liver function normalizes

Monitoring

  • Repeat ALT, AST, ALP, GGT, bilirubin, CBC at 4–6 weeks
  • Lipid panel after 12 weeks of lifestyle modification
  • Watch for: increasing jaundice, dark urine, pale stools, severe RUQ pain, confusion — seek urgent care if any develop
⚠ Important
Hepatocellular injury at this magnitude warrants medical evaluation within 1–2 weeks, not delay until a routine appointment. Should jaundice deepen, mental status change, or right upper quadrant pain become severe, this constitutes an urgent presentation.

Key Questions for Your Physician

  • Should atorvastatin be temporarily held while we identify the cause of the liver enzyme elevation?
  • What viral hepatitis screening do you recommend — comprehensive panel or targeted tests?
  • Given my reported alcohol intake, is there a measurable threshold I should aim for, or is complete abstinence indicated for a defined period?
  • Should I have a FibroScan or other elastography given the duration of suspected liver involvement?
  • What specific symptoms should trigger urgent care vs. routine follow-up?
  • Would a hepatology referral be appropriate at this stage, or after initial workup results return?

What This Means for You

Your blood results show that your liver is currently inflamed — the enzymes that should mostly stay inside liver cells are leaking into your bloodstream at five to seven times the typical amount, which fits the mild yellowing your family noticed.

The most likely contributors, given your profile, are alcohol intake, your statin medication, and possibly fatty liver related to weight and cholesterol patterns. None of these are emergencies, but they do need sorting out — and importantly, all of them are reversible if addressed.

Your kidneys, blood sugar, and urine are all normal. Your hemoglobin is normal. The signal is concentrated in your liver and your fats.

Plan for the next two weeks: schedule a follow-up with your physician, discuss the statin and alcohol questions, get the additional tests listed above, and start the lifestyle adjustments. Most patients with this pattern see meaningful improvement within 6–12 weeks of consistent change.

Analysis Confidence 87%

Confidence reflects the consistency of the laboratory data, the strength of the pattern, and the availability of clinical context. The principal limitation is the absence of viral serologies and imaging at this stage, which would refine the differential.

References

  1. Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol 2017;112(1):18–35.
  2. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999;94(4):1018–22.
  3. Chalasani N, Bonkovsky HL, Fontana R, et al. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury. Gastroenterology 2014;148(7):1340–52.
  4. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023;78(6):1966–86.
  5. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol 2018;69(1):154–81.
  6. EASL Clinical Practice Guidelines on the management of cholestatic liver diseases. J Hepatol 2017;67(1):145–72.
  7. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43(6):1317–25.
  8. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97(9):2969–89.
  9. Kaferle J, Strzoda CE. Evaluation of macrocytosis. Am Fam Physician 2009;79(3):203–8.